Allogen Biologics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Allogen Biologics operates as a subsidiary of Therapeutic Solutions International (TSOI), concentrating on the development and manufacturing of cellular therapies. The company is led by a management team with deep expertise in drug development, regulatory navigation, and intellectual property generation. Its strategic direction appears to be aligned with TSOI's broader portfolio of subsidiary companies targeting various disease areas through biologic platforms.

BiologicsImmunology

Technology Platform

Focus on cellular manufacturing for biologic therapies, leveraging expertise in gene delivery, DNA vaccines, and rapid clinical translation models.

Opportunities

Opportunities lie in capitalizing on the growing demand for scalable cellular manufacturing, potentially serving both internal TSOI subsidiary pipelines and external biotech partners.

The leadership's proven rapid translation model could accelerate time-to-clinic for novel therapies.

Risk Factors

Key risks include complete dependency on parent company funding, an undisclosed and unproven pipeline, intense competition in cell therapy manufacturing, and the inherent technical and regulatory complexities of producing advanced biologic products.

Competitive Landscape

Competes with large CDMOs (e.g., Lonza, Catalent) and other biotech firms in the cell therapy space. Potential differentiation may come from integrated development within the TSOI network and specialized expertise in rapid clinical translation and regulatory strategy.

More companies in Cell & Gene Therapy →More companies in United States →